German pharmaceutical company Bayer says it is considering ways of challenging an Indian court ruling on its anti-cancer drug Nexavar.
A local firm in New Delhi has been granted approval to produce a much cheaper copy.
The Indian company Natco will pay a six per cent royalty on the sales of the product.
Al Jazeera's Prerna Suri reports from the Indian capital.
